Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,257,370
  • Shares Outstanding, K 65,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -248,500 K
  • 60-Month Beta 1.76
  • Price/Sales 3,892.02
  • Price/Cash Flow N/A
  • Price/Book 12.55
Trade AIMT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.33
  • Most Recent Earnings -1.06 on 07/30/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.99
  • Number of Estimates 7
  • High Estimate -0.88
  • Low Estimate -1.23
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +3.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.21 +0.82%
on 09/14/20
34.59 -0.29%
on 10/09/20
+0.29 (+0.85%)
since 09/11/20
3-Month
11.82 +191.79%
on 08/28/20
34.59 -0.29%
on 10/09/20
+18.81 (+119.96%)
since 07/10/20
52-Week
10.09 +241.82%
on 03/17/20
37.00 -6.78%
on 01/16/20
+9.94 (+40.49%)
since 10/11/19

Most Recent Stories

More News
Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021

--- Additional poster exploring preliminary insights on longer-term safety outcomes from ongoing, Phase 3 ARC008 study to be presented -

AIMT : 34.49 (-0.29%)
Seres Therapeutics, Nestle Health Science Announce SER-109 Co-Commercialization License Agreement

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestle Health Science to jointly commercialize SER-109, Seres'...

AIMT : 34.49 (-0.29%)
MCRB : 7.16 (+3.17%)
Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis

Aimmune Therapeutics, a Nestle Health Science company developing pharmaceutical therapies to prevent, manage and treat food and metabolic-related diseases, including exocrine pancreatic insufficiency (EPI),...

AIMT : 34.49 (-0.29%)
CGIX : 4.61 (-2.33%)
Allakos Appoints Baird Radford as Chief Financial Officer

Allakos Inc. (the "Company" or "Allakos") (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird...

AIMT : 34.49 (-0.29%)
ALLK : 109.42 (+1.16%)
FARE Launches Global Research Competition to Develop a Safe & Compassionate Diagnostic Test for Patients with Food Allergies

, /PRNewswire/ -- , the world's leading non-governmental organization engaged in food allergy advocacy and largest private funder of food allergy research, today launched a multi-year competition, the...

AIMT : 34.49 (-0.29%)
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA(R) for up to ~3.5 Years

---- Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time --

AIMT : 34.49 (-0.29%)
European Commission Approves Aimmune's PALFORZIA(R) as First-Ever Treatment for Peanut Allergy in the EU

-- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy --

AIMT : 34.49 (-0.29%)
Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information

NSRGY : 120.4401 (-1.57%)
AIMT : 34.49 (-0.29%)
Uptrend Call Working As Aimmune Therapeu Stock Rises 0.8% (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on August 31st, 2020 at $34.20. In approximately 2 months, Aimmune Therapeu has returned 0.85% as of today's recent price of $34.49.

AIMT : 34.49 (-0.29%)
Uptrend Call Working As Aimmune Therapeu Stock Rises 0.8% (AIMT)

SmarTrend identified an Uptrend for Aimmune Therapeu (NASDAQ:AIMT) on August 31st, 2020 at $34.20. In approximately 2 months, Aimmune Therapeu has returned 0.85% as of today's recent price of $34.49.

AIMT : 34.49 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 34.59
1st Resistance Point 34.54
Last Price 34.49
1st Support Level 34.46
2nd Support Level 34.43
3rd Support Level N/A

See More

52-Week High 37.00
Last Price 34.49
Fibonacci 61.8% 26.72
Fibonacci 50% 23.55
Fibonacci 38.2% 20.37
52-Week Low 10.09

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar